Table 4 Surgical outcomes, neoadjuvant treatment responses, and adjuvant treatment types according to the treatment group.
Arm A | Arm B | p value | |
|---|---|---|---|
n (%) | n (%) | ||
Operation type | 0.94 | ||
BCS | 22 (44.0) | 41 (44.6) | |
MRM | 28 (56.0) | 51 (55.4) | |
Axilla staging | 0.92 | ||
SLND | 33 (66.0) | 60 (65.2) | |
ALND | 17 (34.0) | 32 (34.8) | |
Complete response (ypT0N0) | 25 (50.0) | 47 (51.1) | 0.90 |
Surgical margin positivity | 0 (0.0) | 1 (1.2) | 0.70 |
Grade | 0.12 | ||
Gx | 18 (36.0) | 45 (48.9) | |
G1 | 11 (22.0) | 9 (9.8) | |
G2 | 17 (34.0) | 26 (28.3) | |
G3 | 4 (8.0) | 12 (13.0) | |
Lymphovascular invasion | 9 (23.7) | 22 (25.6) | 0.82 |
Perineural invasion | 3 (7.9) | 13 (15.1) | 0.38 |
Adjuvant treatment | 0.001a | ||
AC + trastuzumab | 2 (4.0) | 0 (0.0) | |
Trastuzumab | 34 (68.0) | 75 (81.5) | |
Trastuzumab + pertuzumab | 12 (24.0) | 5 (5.4) | |
Trastuzumab emtansine (T-DM1) | 2 (4.0) | 12 (13.0) | |
Adjuvant treatment completion | 0.08 | ||
Yes | 42 (84.0) | 85 (92.4) | |
No | 0 (0.0) | 2 (2.2) | |
Continues | 8 (16.0) | 5 (5.4) | |
Relapse status | 1 (2.0) | 5 (5.4) | 0.42 |
Relapse site | 0.66 | ||
Local | 0 (0.0) | 1 (1.1) | |
Liver | 0 (0.0) | 1 (1.1) | |
Lymph node | 0 (0.0) | 2 (2.1) | |
Central nervous system | 0 (0.0) | 1 (1.1) | |
Local-bone-lymph node | 1 (2.0) | 0 (0.0) | |
Relapse ER/PR status | 0.16 | ||
ER and/or PR-positive | 1 (2.0) | 0 (0.0) | |
ER and PR-negative | 0 (0.0) | 5 (5.4) | |
Relapse HER-2 status | 0.50 | ||
Positive | 0 (0.0) | 4 (4.3) | |
Negative | 1 (2.0) | 1 (1.1) | |
